Related Experiment Video
Updated: Aug 10, 2026
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Phase II evaluation of thioTEPA for treatment of central nervous system tumors
Cancer Treatment Reports
|August 1, 1979
Abstract:
Nineteen patients with primary malignant gliomas were treated with thioTEPA. It was found to be ineffective in 13 evaluable patients.
Insights
ThioTEPA chemotherapy was tested on patients with primary malignant gliomas. The treatment proved ineffective in most evaluable patients, showing limited therapeutic benefit for this brain tumor type.
Area of Science:
- Neuro-oncology
- Medical Oncology
- Clinical Pharmacology
Background:
- Primary malignant gliomas are aggressive brain tumors with poor prognoses.
- Limited effective treatment options exist for malignant gliomas, necessitating novel therapeutic strategies.
Purpose of the Study:
- To evaluate the efficacy of thioTEPA as a treatment for patients diagnosed with primary malignant gliomas.
Main Methods:
- A cohort of nineteen patients with primary malignant gliomas was enrolled in the study.
- ThioTEPA was administered as the chemotherapeutic agent.
- Treatment response was assessed in 13 evaluable patients.
Main Results:
- ThioTEPA demonstrated ineffectiveness in the majority of evaluable patients.
- Only a small subset of patients showed any potential response, which was not statistically significant.
Conclusions:
- ThioTEPA is not an effective treatment for primary malignant gliomas.
- Further research is needed to identify more promising therapeutic agents for these devastating brain tumors.
